Molybdenum cofactor biosynthetic machinery and molybdoenzymes (MoCo/Molybdoenzymes)

The molybdenum cofactor (MoCo) biosynthetic machinery and molybdoenzymes represent a critical metabolic system responsible for the synthesis of the molybdenum-containing pterin cofactor and its subsequent incorporation into specific enzymes. In humans, this system supports four essential molybdoenzymes: sulfite oxidase, xanthine oxidoreductase, aldehyde oxidase, and the mitochondrial amidoxime reducing component (mARC). These enzymes are vital for the detoxification of sulfite, the catabolism of purines into uric acid, and the metabolism of various xenobiotics and drugs. Defects in the biosynthetic machinery, such as mutations in MOCS1 or MOCS2, lead to Molybdenum Cofactor Deficiency (MoCD), a devastating neonatal neurological disorder characterized by intractable seizures and rapid neurodegeneration due to toxic sulfite accumulation. Therapeutic interventions include cofactor replacement therapy (e.g., Fosdenopterin for MoCD Type A) and the use of inhibitors like allopurinol to manage conditions like gout by targeting specific molybdoenzymes.

Other names

Molybdenum cofactor biosynthesis pathwayMoCo biosynthetic pathwayMolybdoenzyme systemMolybdenum metabolism

Fosdenopterin acts as a substrate replacement therapy (cyclic pyranopterin monophosphate) to bypass biosynthetic defects in MoCD Type A. Xanthine oxidase inhibitors like allopurinol and febuxostat bind to the molybdenum center of the enzyme to inhibit uric acid production.